Amgen: Lung Neoplasms trials

The registry lists 32 Lung Neoplasms studies with Amgen as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 10Phase 2 16Phase 3 7Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
• A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)TerminatedNCT05267470Phase 1Results posted
• AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)CompletedNCT04885998Phase 1Results posted
• Study of AMG 160 in Subjects With Non-Small Cell Lung CancerTerminatedNCT04822298Phase 1Results posted
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung CancerCompletedNCT01987232Phase 1/2Results posted
• Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01966003Phase 3Results posted
• Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung CancerCompletedNCT01951586Phase 2Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic ChemotherapyCompletedNCT00883181Results posted
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedNCT00858364Phase 3Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00413283Phase 2Results posted
• Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00094835Phase 1/2Results posted
• Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerApproved for marketingNCT06064500
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT05361395Phase 1
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
• A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyCompletedNCT03776032Phase 3
• Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerCompletedNCT01666977Phase 1/2
• A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerCompletedNCT00534027Phase 1/2
• A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- BevacizumabCompletedNCT00508625Phase 2
• MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyTerminatedNCT00460317Phase 3
• Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung CancerWithdrawnNCT00352950Phase 1
• Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyCompletedNCT00120679Phase 2
• A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaCompletedNCT00119613Phase 3
• Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During ChemotherapyCompletedNCT00115206Phase 4
• ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00101920Phase 2
• Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00094822
• Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesCompletedNCT00036023Phase 2
• ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00034346Phase 2
• Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerStatus unknownNCT00033722Phase 2
• T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyStatus unknownNCT00022243Phase 2
• Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerStatus unknownNCT00006215Phase 2